Guselkumab

• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 Phase III 13 countries Janssen Cilag International
• Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a rand… Pending
  2025-523551-54-00 Phase IV 1 country Azienda Sanitaria Universitaria Friuli Centrale
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Pending
  2025-524573-16-00 Phase IV 1 country i-GETAID
• Guselkumab intervention and diet evaluation for pouchitis Recruiting
  2025-521683-35-00 Phase IV 1 country UZ Leuven
• Proactive TDM versus standard use of biologics in psoriasis (HELIOS) Recruiting
  2023-509637-39-00 Phase IV 1 country Universitair Ziekenhuis Gent
• A Long-term Extension Study of Guselkumab in Pediatric Participants Recruiting
  2023-509560-16-00 Phase III 8 countries Janssen Cilag International
• Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patient… Recruiting
  2024-512459-19-00 Phase IV 1 country Universitaetsklinikum Erlangen AöR
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-504735-41-00 Phase III 9 countries Janssen - Cilag International
• Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting
  2022-500311-39-00 Phase IV 2 countries UZ Leuven
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended
  2023-504040-34-01 Phase III 8 countries Janssen - Cilag International
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2022-502238-22-00 Phase III 8 countries Janssen - Cilag International
• Investigation of tissue-resident memory T-cells and disease MEMory in psoriasis during GUSelkumab treatment. The GUSMEM study. Ended
  2023-503776-25-00 Phase IV 1 country Aarhus University Hospital
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended
  2023-504719-34-00 Phase III 9 countries Janssen - Cilag International
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended
  2023-504741-32-00 Phase II 19 countries Janssen - Cilag International
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended
  2023-504743-13-00 Phase II 20 countries Janssen - Cilag International
• Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Ended
  2023-504740-33-00 Phase III 11 countries Janssen - Cilag International
• GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended
  2023-504737-41-00 Phase III 10 countries Janssen - Cilag International
• Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended
  2023-504715-33-00 Phase III 5 countries Janssen - Cilag International
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended
  2023-504734-21-00 Phase III 14 countries Janssen - Cilag International
• Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended
  2023-504716-15-00 Phase IV 11 countries Janssen - Cilag International
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504718-31-00 Phase II/III 13 countries Janssen - Cilag International
• A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Ended
  2023-503378-19-00 Phase III 5 countries Janssen - Cilag International
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended
  2023-504736-18-00 Phase II/III 13 countries Janssen - Cilag International

Showing 1–24 of 26 trials